Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $CNMD
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/6/2025 | $85.00 → $70.00 | Overweight → Neutral | Analyst |
2/1/2024 | $119.00 → $129.00 | Buy | Needham |
5/22/2023 | $140.00 | Buy | CL King |
3/27/2023 | $124.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
3/21/2023 | $96.00 | Equal Weight | Wells Fargo |
10/12/2022 | $85.00 | Hold | Jefferies |
3/2/2022 | $155.00 | Neutral | BofA Securities |
1/21/2022 | $158.00 → $150.00 | Buy | Needham |
CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t
CONMED Corporation Adds Mark Kaye to its Board of Directors
CONMED Corporation (NYSE:CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. "My fellow directors and I are extremely pleased to welcome Mark to the board," said Martha Goldberg Aronson, Chair of CONMED's Board of Directors. "Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a strong background and expertise in both corporate governance and healthcare. Mark's skills and insights will help guide CONMED's future direction." "Mark is an outstanding addition to our board," said Patrick Beyer, President and C
CONMED Corporation Announces Quarterly Cash Dividend
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on
CONMED downgraded by Analyst with a new price target
Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously
Needham reiterated coverage on CONMED with a new price target
Needham reiterated coverage of CONMED with a rating of Buy and set a new price target of $129.00 from $119.00 previously
CL King initiated coverage on CONMED with a new price target
CL King initiated coverage of CONMED with a rating of Buy and set a new price target of $140.00
Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)
4 - CONMED Corp (0000816956) (Issuer)
Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)
4 - CONMED Corp (0000816956) (Issuer)
Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)
4 - CONMED Corp (0000816956) (Issuer)
EVP, STRAT & CORP DEVT Shagory Peter K exercised 4,500 shares at a strike of $55.42 and covered exercise/tax liability with 4,316 shares, increasing direct ownership by 5% to 3,897 units (SEC Form 4)
4 - CONMED Corp (0000816956) (Issuer)
Vice President QA and RA Lalomia Brent converted options into 75 shares and covered exercise/tax liability with 26 shares, increasing direct ownership by 5% to 1,006 units (SEC Form 4)
4 - CONMED Corp (0000816956) (Issuer)
SEC Form 4 filed by VP Global Manufacturing Clifford Edward A.
4 - CONMED Corp (0000816956) (Issuer)
CONMED Corporation filed SEC Form 8-K: Leadership Update
8-K - CONMED Corp (0000816956) (Filer)
CONMED Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
8-K - CONMED Corp (0000816956) (Filer)
SEC Form 10-K filed by CONMED Corporation
10-K - CONMED Corp (0000816956) (Filer)
Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors
CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am
CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t
CONMED Corporation Announces Quarterly Cash Dividend
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on
CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results
CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted net earnings per share (GAAP) of $1.05 in the fourth quarter of 2023. Adjusted diluted net earnings per share(1) were $1.34, an increase of 26.4% compared to the fourth quarter of 2023. Full-Year 2024 Highlights
Amendment: SEC Form SC 13G/A filed by CONMED Corporation
SC 13G/A - CONMED Corp (0000816956) (Subject)
Amendment: SEC Form SC 13G/A filed by CONMED Corporation
SC 13G/A - CONMED Corp (0000816956) (Subject)
SEC Form SC 13G/A filed by CONMED Corporation (Amendment)
SC 13G/A - CONMED Corp (0000816956) (Subject)